Incidences of emerging/re-emerging deadly viral infections have significantly affected human health despite extraordinary progress in the area of biomedical knowledge. The best examples are the recurring outbreaks of dengue and chikungunya fever in tropical and sub-tropical regions, the recent epidemic of Zika in the Americas and the Caribbean, and the SARS, MERS, and influenza A outbreaks across the globe. The established natural reservoirs of human viruses are mainly farm animals, and, to a lesser extent, wild animals and arthropods. The intricate “host-pathogen-environment” relationship remains the key to understanding the emergence/re-emergence of pathogenic viruses. High population density, rampant constructions, poor sanitation, changing climate, and the introduction of anthropophilic vectors create selective pressure on host-pathogen reservoirs. Nevertheless, the knowledge and understanding of such zoonoses and pathogen diversity in their known non-human reservoirs are very limited. Prevention of arboviral infections using vector control methods has not been very successful. Currently, new approaches to protect against food-borne infections, such as consuming only properly cooked meats and animal products, are the most effective control measures. Though significant progress in controlling human immunodeficiency virus and hepatitis viruses has been achieved, the unpredictable nature of evolving viruses and the rare occasions of outbreaks severely hamper control and preventive modalities.

Keywords:
Emerging infections, Novel viruses, Viral outbreaks, Virus evolution
1.
Krause RM: The origin of plagues: old and new. Science 1992;257:1073-1078.
2.
Wever PC, van Bergen L: Death from 1918 pandemic influenza during the First World War: a perspective from personal and anecdotal evidence. Influenza Other Respir Viruses 2014;8:538-546.
3.
Dawood FS, Iuliano AD, Reed C, et al: Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012;12:687-695.
4.
WHO: Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. http://www.who.int/csr/sars/country/table2004_04_21/en/.
5.
Gardner SD, Field AM, Coleman DV, Hulme B: New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1971;1:1253-1257.
6.
Padgett BL, Walker DL, ZuRhein GM et al.: Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971;1:1257-1260.
7.
Feng H, Shuda M, Chang Y, Moore PS: Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008;319:1096-1100.
8.
Paweska T, Sewlall NH, Ksiazek TG, et al: Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerg Infect Dis 2009;15:1598-1602.
9.
WHO: Lassa fever fact sheet 2016. http://www.who.int/mediacentre/factsheets/fs179/en/.
10.
Lu S, Xi X, Zheng Y, et al: Analysis of the clinical characteristics and treatment of two patients with avian influenza virus (H7N9). Biosci Trends 2013;7:109-112.
11.
Khan G: A novel coronavirus capable of lethal human infections: an emerging picture. Virol J 2013;10:66-65.
12.
Musso D, Gubler DJ: Zika Virus. Clin Microbiol Rev 2016;29:487-524.
13.
Cleaveland S, Laurenson MK, Taylor LH: Diseases of humans and their domestic mammals: pathogen characteristics, host range and the risk of emergence. Phil Trans R Soc Lond B 2011;356:991-999.
14.
Taylor LH, Latham SM, Woolhouse MEJ: Risk factors for human disease emergence. Phil Trans R Soc Lond B 2013;356:983-989.
15.
Woolhouse MEJ, Gowtage-Sequeria S: Host range and emerging and re-emerging pathogens. Emerg Infect Dis 2005;11:1842-1847.
16.
Kilpatrick AM, Randolph SE: Drivers, dynamics, and control of emerging vector-borne zoonotic diseases. Lancet 2012;380:1946-1955.
17.
Cleaveland S, Haydon DT, Taylor L: Overviews of pathogen emergence: which pathogens emerge, when and why? Curr Top Microbiol Immunol 2007;315:85-111.
18.
Corman VM, Eckerle I, Bleicker T, et al: Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill 2012;17:pii: 20285.
19.
Anderson LJ, Tong S: Update on SARS research and other possibly zoonotic coronaviruses. Int J Antimicrob Agents 2010;36:S21-S25.
20.
McElhinney LM, Marston DA, Leech S, et al: Molecular epidemiology of bat lyssaviruses in europe. Zoo Pub Health 2013;60:35-45.
21.
McCall BJ, Epstein JH, Neill AS, et al: Potential exposure to Australian bat lyssavirus, Queensland, 1996-1999. Emerg Infect Dis 2000;6:259-264.
22.
Allworth A, Murray K, Morgan J: A human case of encephalitis due to a Lyssavirus recently identified in fruit bats. Commun Dis Intell 1996;20:504-510.
23.
Hanna JN, Carney IK, Smith GA, et al: Australian bat lyssavirus infection: a second human case, with a long incubation period. Med J Aust 2000;172:597-599.
24.
Fooks A: The challenge of new and emerging lyssaviruses. Expert Rev Vaccines 2004;3:333-336.
25.
CDC: Rodents in the United States that carry hantavirus. http://www.cdc.gov/hantavirus/rodents/index.html.
26.
Ge X, Yang W, Pan H, et al: Fugong virus, a novel hantavirus harbored by the small oriental vole (Eothenomys eleusis) in China. Virol J 2016;13:27-32.
27.
Pavio N, Meng XJ, Doceul V: Zoonotic origin of hepatitis E. Curr Opin Virol 2015;10:34-41.
28.
Widén F: Hepatitis E as a zoonosis. Adv Exp Med Biol 2016;948:61-71.
29.
Spandole S, Cimponeriu D, Berca LM, Mihăescu G: Human anelloviruses: an update of molecular, epidemiological and clinical aspects. Arch Virol 2015;160:893-908.
30.
Duffy M R, ChenT-H, et al: Zika virus outbreak on Yap Island, Federated States of Micronesia. New Eng J Med 2009;360:2536-2543.
31.
PAHO: Regional Zika epidemiological update (Americas) 2016. http://www.paho.org/hq/index.php?option=com_content&id=11599&Itemid=41691.
32.
Pesko KN, Ebel GD: West Nile virus population genetics and evolution. Infect Genet Evol 2012;12:181-190.
33.
Mertens M, Schmidt K, Ozkul A, Groschup MH: The impact of Crimean-Congo hemorrhagic fever virus on public health. Antiviral Res 2013;98:248-260.
34.
Yu XJ, Liang MF, Zhang SY, et al: Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med 2011;364:1523-1532.
35.
Simmonds P: Reconstructing the origins of human hepatitis viruses. Phil Trans R Soc Lond B 2011;356:1013-1026.
36.
Kitchen A, Shackelton LA, Holmes EC: Family level phylogenies reveal modes of macroevolution in RNA viruses. Proc Natl Acad Sci USA 2011;108:238-243.
37.
Wolfe ND, Dunavan CP, Diamond J: Origins of major human infectious diseases. Nature 2007;447:279-283.
38.
Woolhouse MEJ, Adair K: The diversity of human viruses. Future Virol 2013;8:159-171.
39.
Shukla P, Nguyen HT, Torian U, et al: Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant. Proc Natl Acad Sci USA 2011;108:2438-2443.
40.
Grenfell BT, Pybus OG, Gog JR, et al: Unifying the epidemiological and evolutionary dynamics of pathogens. Science 2004;303:327-332.
41.
Holmes EC: The Evolution and Emergence of RNA Viruses. Oxford, Oxford University Press, 2009.
42.
Tsetsarkin KA, Weaver SC: Sequential adaptive mutations enhance efficient vector switching by chikungunya virus and its epidemic emergence. PLoS Pathog 2011;7:e1002412.
43.
Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S: A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 2007;3:e201.
44.
Abushouk AI, Negida A, Ahmed H: An updated review of Zika virus. J Clin Virol 2016;84:53-58.
45.
Trento A, Galiano M, Videla C, Carballal G, Garcia-Barreno B, et al: Major changes in the G protein of human respiratory syncytial virus isolates introduced by a duplication of 60 nucleotides. J Gen Virol 2003;84:3115-3120.
46.
Eshaghi A, Duvvuri VR, Lai R, Nadarajah JT, Li A, et al: Genetic variability of human respiratory syncytial virus A strains circulating in Ontario: a novel genotype with a 72 nucleotide G gene duplication. PLoS One 2012;7:e32807.
47.
Ahmed A, Haider SH, Parveen S, et al: Co-circulation of 72-bp duplication group A and 60-bp duplication group B respiratory syncytial virus (RSV) strains in Riyadh, Saudi Arabia during 2014. PLoS One 2016;11:e0166145
48.
Duvvuri VR, Granados A, Rosenfeld P, Bahl J, Eshaghi A, et al: Genetic diversity and evolutionary insights of respiratory syncytial virus A ON1 genotype: global and local transmission dynamics. Sci Rep 2015;5:14268.
49.
Trento A, Casas I, Calderon A, Garcia-Garcia ML, Calvo C, et al: Ten years of global evolution of the human respiratory syncytial virus BA genotype with a 60-nucleotide duplication in the G protein gene. J Virol 2010;84:7500-7512.
50.
Parveen S, Sullender WM, Fowler K, Lefkowitz EJ, Kapoor SK, Broor S: Genetic variability in the G protein gene of group A and B respiratory syncytial viruses from India. J Clin Microbiol 2006;44:3055-3064.
51.
Anderson RM, Fraser C, Ghani AC, et al: Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic. Phil Trans R Soc Lond B 2004;359:1091-1105.
52.
Hufnagel L, Brockmann D, Geisel T: Forecast and control of epidemics in a globalized world. Proc Natl Acad Sci USA 2004;101:15124-15129.
53.
Kucharski AJ, Funk S, Eggo RM, et al: Transmission dynamics of Zika virus in island populations: a modeling analysis of the 2013-14 French Polynesia outbreak. PLoS Negl Trop Dis 2016;10:e0004726.
54.
Li WD, Shi ZL, Yu M, et al: Bats are natural reservoirs of SARS-like coronaviruses. Science 2005;310:676-679.
55.
Guan Y, Zheng BJ, He YQ, et al: Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003;302:276-278.
56.
Bofill-Mas S, Formiga-Cruz M, Clemente-Casares P, et al: Potential transmission of human polyomaviruses through the gastrointestinal tract after exposure to virions or viral DNA. J Virol 2001;75:10290-10299.
57.
Deeba F, Islam A, Kazim SN, Naqvi IH, Broor S, Ahmed A, Parveen S: Chikungunya virus: recent advances in epidemiology, host pathogen interaction and vaccine strategies. Pathog Dis 2016;74:ftv119.
58.
Parvez MK: Chronic hepatitis E infection: risks and controls. Intervirol 2013;56:213-216.
59.
French CE, McKenzie BC, Coope C, et al: Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review. Influenza Other Respir Viruses 2016;10:268-290.
60.
Afreen N, Naqvi IH, Baroor S, Ahmed A, Parveen S: Phylogenetic and molecular clock analysis of dengue serotype 1 and 3 from New Delhi, India. PLoS One 2015;10:e0141628.
61.
Tazeen A, Afreen N, Abdullah M, et al: Occurrence of co-infection with dengue viruses during 2014 in New Delhi, India. Epidemiol Infect 2016;13:1-11.
62.
Lahariya C, Pradhan S: Emergence of chikungunya virus in Indian subcontinent after 32 years: a review. J Vector borne Dis 1996;43:151-157.
63.
Afreen N, Deeba F, Khan WH, et al: Molecular characterization of dengue and chikungunya virus strains circulating in New Delhi, India. Microbiol Immunol 2014;58:688-696.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.